PL2799090T3 - Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych - Google Patents

Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych

Info

Publication number
PL2799090T3
PL2799090T3 PL14165008T PL14165008T PL2799090T3 PL 2799090 T3 PL2799090 T3 PL 2799090T3 PL 14165008 T PL14165008 T PL 14165008T PL 14165008 T PL14165008 T PL 14165008T PL 2799090 T3 PL2799090 T3 PL 2799090T3
Authority
PL
Poland
Prior art keywords
preparing
pharmaceutical formulation
contrast agents
agents
contrast
Prior art date
Application number
PL14165008T
Other languages
English (en)
Other versions
PL2799090T5 (pl
Inventor
Dominique Meyer
Claire Corot
Marc Port
Vincent Barbotin
Bruno Bonnemain
Original Assignee
Guerbet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40955314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2799090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0851055A external-priority patent/FR2927539B1/fr
Application filed by Guerbet filed Critical Guerbet
Publication of PL2799090T3 publication Critical patent/PL2799090T3/pl
Publication of PL2799090T5 publication Critical patent/PL2799090T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL14165008.5T 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych PL2799090T5 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR0851055A FR2927539B1 (fr) 2008-02-19 2008-02-19 Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
EP08154745 2008-04-17
US12/155,997 US20090208421A1 (en) 2008-02-19 2008-06-12 Process for preparing a pharmaceutical formulation of contrast agents
EP13154448.8A EP2591807A1 (en) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents
EP09712403.6A EP2242515B9 (en) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents
EP14165008.5A EP2799090B2 (en) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents

Publications (2)

Publication Number Publication Date
PL2799090T3 true PL2799090T3 (pl) 2017-08-31
PL2799090T5 PL2799090T5 (pl) 2020-07-13

Family

ID=40955314

Family Applications (3)

Application Number Title Priority Date Filing Date
PL14165006T PL2799089T3 (pl) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents
PL09712403T PL2242515T3 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych
PL14165008.5T PL2799090T5 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL14165006T PL2799089T3 (pl) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents
PL09712403T PL2242515T3 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych

Country Status (17)

Country Link
US (6) US20090208421A1 (pl)
EP (6) EP2799090B2 (pl)
JP (3) JP5469615B2 (pl)
KR (1) KR101063060B1 (pl)
CN (1) CN101977633B (pl)
BR (1) BRPI0908221B1 (pl)
CA (1) CA2714118C (pl)
CY (2) CY1115259T1 (pl)
DE (1) DE202008010019U1 (pl)
DK (3) DK2242515T3 (pl)
ES (3) ES2477541T3 (pl)
HR (2) HRP20140537T1 (pl)
HU (2) HUE030219T2 (pl)
LT (2) LT2799089T (pl)
PL (3) PL2799089T3 (pl)
PT (3) PT2799089T (pl)
WO (1) WO2009103744A2 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2945448B1 (fr) * 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
EP2338874A1 (en) * 2009-12-16 2011-06-29 Bracco Imaging S.p.A Process for the preparation of chelated compounds
WO2014107663A2 (en) * 2013-01-07 2014-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
EP2786768A1 (en) * 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
ES2626582T5 (es) 2013-04-26 2022-10-07 Guerbet Sa Formulación de producto de contraste y su procedimiento de preparación asociado
KR101466602B1 (ko) * 2013-05-31 2014-12-01 동국제약 주식회사 메글루민 가도테레이트를 포함하는 조영제 조성물의 제조방법
AT516104B1 (de) * 2014-07-31 2016-08-15 Sanochemia Pharmazeutika Ag Verfahren zum Herstellen einer flüssigen pharmazeutischen Zubereitung
KR101646211B1 (ko) * 2014-11-12 2016-08-05 (주)디아이테크 자기공명영상용 조영제의 제조방법
GB201421163D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Formulations of metal complexes
GB201421162D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations
US20170035461A1 (en) * 2015-08-03 2017-02-09 Jeffery Deal Reversible tattoo colorant and method
DE102015013939A1 (de) 2015-09-15 2017-03-16 be imaging GmbH Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen
EP3183009B1 (en) * 2015-09-30 2023-08-09 Duke University Contrast agents for magnetic resonance imaging
KR101625656B1 (ko) * 2015-10-16 2016-05-30 최경석 자기공명영상용 조영제의 제조방법
US11110185B2 (en) 2015-11-30 2021-09-07 Ge Healthcare As Combination formulation
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
EP3789044A1 (de) * 2016-10-28 2021-03-10 B.E. Imaging GmbH Verfahren zur herstellung von pharmazeutischen formulierungen enthaltend chelatkomplexe von gadolinium mit reduziertem gehalt an toxischen verunreinigungen
JP7034160B2 (ja) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
HUE050402T2 (hu) 2016-12-21 2020-12-28 Ge Healthcare As MRl képalkotó szerként alkalmazható tetraazabiciklo-makrociklus alapú mangán-kelát vegyületek
WO2018125916A1 (en) * 2016-12-29 2018-07-05 Inventure, LLC Solvent-free gadolinium contrast agents
US20190269805A1 (en) * 2016-12-29 2019-09-05 Inventure, LLC Solvent-free gadolinium contrast agents
IL313115A (en) 2017-05-05 2024-07-01 Centre For Probe Dev And Commercialization R1–IGF monoclonal antibodies and their use
JP2020518673A (ja) 2017-05-05 2020-06-25 フュージョン・ファーマシューティカルズ・インコーポレイテッド 二官能性キレートの薬物動態増強及びその使用
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2019020662A1 (de) * 2017-07-27 2019-01-31 Sanochemia Pharmazeutika Ag Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen
FR3072281B1 (fr) * 2017-10-13 2020-12-04 Nh Theraguix Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs
JP7332600B2 (ja) 2017-12-20 2023-08-23 ゼネラル・エレクトリック・カンパニイ アニオン性キレート化合物
AT521001B1 (de) 2018-02-23 2020-10-15 Sanochemia Pharmazeutika Ag Herstellungsverfahren für ein Kontrastmittel
PE20211471A1 (es) * 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos
JP2022517193A (ja) * 2019-01-03 2022-03-07 アイオンパス， インク． イオンビームイメージングのための組成物および試薬
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
WO2021078726A1 (en) * 2019-10-25 2021-04-29 Bracco Imaging Spa Pharmaceutical compositions of gd-based contrast agents
GB201919073D0 (en) 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
TWI779284B (zh) * 2020-05-06 2022-10-01 商之器科技股份有限公司 用於影像資料標註的裝置
IL298961A (en) 2020-06-10 2023-02-01 Justesa Imagen S A U A process for obtaining high-purity meglumine gadotrate methotrexate (DOTA) and its use for the preparation of injectable galenic formulations
CN113801071B (zh) * 2021-09-14 2023-04-07 安徽普利药业有限公司 一种钆特酸葡甲胺的精制方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) † 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US5082649A (en) 1987-06-30 1992-01-21 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonance imaging agents by addition of calcium ions
FR2596992B1 (fr) † 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic
DE3640708C2 (de) * 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
US5049667A (en) † 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
WO1989000052A1 (en) * 1987-06-30 1989-01-12 Mallinckrodt, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonants imaging agents and x-ray contrast agents
IE66694B1 (en) * 1988-09-27 1996-01-24 Nycomed Salutar Inc Chelate compositions
JPH02173483A (ja) 1988-12-23 1990-07-04 Komatsu Ltd 高速流量制御弁
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US4967447A (en) 1989-09-25 1990-11-06 Romaine Jeffrey L Fish slicer and method of frying fish
US5650133A (en) † 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
GB9000564D0 (en) 1990-01-10 1990-03-14 Dow Rheinmuenster Modified polyoxyethlene epoxy resin amphiphiles and stable aqueous epoxy dispersions thereof
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
US7385041B2 (en) * 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
SG52470A1 (en) * 1992-04-13 1998-09-28 Dow Chemical Co Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
FR2736051B3 (fr) * 1995-06-29 1997-09-26 Guerbet Sa Complexes metalliques de polyaminoacides, leur procede de preparation et leur utilisation en imagerie diagnostique
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US7048907B2 (en) * 2001-02-05 2006-05-23 Biophysics Assay Laboratory, Inc. Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
EP1542709A2 (en) * 2002-08-06 2005-06-22 EPIX Pharmaceuticals, Inc. Peptide aggregates
WO2007002109A2 (en) 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
KR20080103562A (ko) 2006-03-15 2008-11-27 말린크로트, 인코포레이티드 치환된 방향족 잔기 및 그의 유도체를 갖는 킬레이팅 컨쥬게이트
WO2007121453A2 (en) 2006-04-17 2007-10-25 The Regents Of The University Of California 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
US20090208421A1 (en) * 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents

Also Published As

Publication number Publication date
BRPI0908221B1 (pt) 2021-07-13
EP3159014A1 (en) 2017-04-26
DK2799089T3 (en) 2016-11-21
CY1115259T1 (el) 2017-01-04
HUE031091T2 (en) 2017-06-28
JP5469615B2 (ja) 2014-04-16
HRP20161312T2 (hr) 2018-01-26
EP2799089B9 (en) 2017-09-06
EP2799089A3 (en) 2015-03-04
DK2242515T3 (da) 2014-07-07
KR101063060B1 (ko) 2011-09-07
JP5985523B2 (ja) 2016-09-06
ES2593127T5 (es) 2020-09-25
EP2799089A2 (en) 2014-11-05
US20160235868A1 (en) 2016-08-18
EP2799090A3 (en) 2015-01-14
LT2799090T (lt) 2016-10-10
EP2799089B1 (en) 2016-08-03
BRPI0908221A2 (pt) 2018-03-20
PT2799089T (pt) 2016-10-25
WO2009103744A2 (en) 2009-08-27
US20160235867A1 (en) 2016-08-18
US20090208421A1 (en) 2009-08-20
DE202008010019U1 (de) 2009-07-02
CA2714118C (en) 2017-03-28
LT2799089T (lt) 2016-11-10
US20130336898A1 (en) 2013-12-19
EP2242515A2 (en) 2010-10-27
ES2597782T3 (es) 2017-01-23
EP3620179A1 (en) 2020-03-11
EP2799090A2 (en) 2014-11-05
CY1118985T1 (el) 2018-01-10
HUE030219T2 (en) 2017-04-28
PL2242515T3 (pl) 2014-08-29
US9907866B2 (en) 2018-03-06
DK2799090T4 (da) 2020-05-18
JP2014114306A (ja) 2014-06-26
HRP20161312T1 (hr) 2016-12-16
EP2242515B1 (en) 2014-04-02
DK2799090T5 (en) 2017-04-18
EP2799090B2 (en) 2020-03-04
JP2011514334A (ja) 2011-05-06
US20110129425A1 (en) 2011-06-02
WO2009103744A3 (en) 2009-12-17
US9655983B2 (en) 2017-05-23
PL2799090T5 (pl) 2020-07-13
CN101977633B (zh) 2012-08-29
JP6422460B2 (ja) 2018-11-14
EP2799090B9 (en) 2016-12-21
CA2714118A1 (en) 2009-08-27
ES2593127T9 (es) 2017-05-08
HRP20140537T1 (hr) 2014-07-18
ES2593127T3 (es) 2016-12-05
CN101977633A (zh) 2011-02-16
EP2799090B1 (en) 2016-06-29
US20170189563A1 (en) 2017-07-06
PT2799090T (pt) 2016-09-28
PL2799089T3 (pl) 2017-08-31
JP2016117778A (ja) 2016-06-30
US9636427B2 (en) 2017-05-02
EP2242515B9 (en) 2014-10-01
ES2477541T3 (es) 2014-07-17
PT2242515E (pt) 2014-07-11
KR20100133976A (ko) 2010-12-22
EP2591807A1 (en) 2013-05-15
DK2799090T3 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
HRP20161312T1 (hr) Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
IL237642A (en) METHOD FOR PREPARING PHARMACEUTICAL MATERIALS
IL211701A0 (en) Process for the preparation of bendamustine
HK1169960A1 (en) Pharmaceutical formulation
IL207526A0 (en) Process for preparing 2-amino-5-cyanobenzoic acid derivatives
AP3050A (en) New Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions comprising them
HK1157785A1 (en) Process for preparing a mixture of lactide derivatives
HK1156046A1 (zh) 種用於製備胰島素化合物的方法
HK1155742A1 (en) Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
IL213354A0 (en) Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
EP2306998A4 (en) PHARMACEUTICAL FORMULATION
HUP0700756A2 (en) Process for the preparation of pharmaceutical intermediers
HK1167692A1 (en) Process for the preparation of a iodinating agent
GB2444572B (en) A process for the preparation of a stable anhydrous anthelmintic formulation
PL2276762T3 (pl) Sposób wytwarzania jałowego doripenemu
HU0800239D0 (en) Process for preparation of cyclohexanol derivatives
GB0805292D0 (en) Pharmaceutical formulation
GB0805953D0 (en) Process for the manufacture of a pharmaceutical product
SI2321312T1 (sl) Postopek za pripravo paliperidona
EP2250178A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF TRIAZOL-BENZODIAZEPINE DERIVATIVES